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Abstract
Background: Acute inflammatory reactions are a frequently occurring, tissue destructing phenomenon in
infectious- as well as autoimmune diseases, providing clinical challenges for early diagnosis. In leprosy, an
infectious disease initiated by Mycobacterium leprae (M. leprae), these reactions represent the major cause of
permanent neuropathy. However, laboratory tests for early diagnosis of reactional episodes which would
significantly contribute to prevention of tissue damage are not yet available.
Although classical diagnostics involve a variety of tests, current research utilizes limited approaches for biomarker
identification. In this study, we therefore studied leprosy as a model to identify biomarkers specific for inflammatory
reactional episodes.
Methods: To identify host biomarker profiles associated with early onset of type 1 leprosy reactions, prospective
cohorts including leprosy patients with and without reactions were recruited in Bangladesh, Brazil, Ethiopia and Nepal.
The presence of multiple cyto-/chemokines induced by M. leprae antigen stimulation of peripheral blood
mononuclear cells as well as the levels of antibodies directed against M. leprae-specific antigens in sera, were
measured longitudinally in patients.
Results: At all sites, longitudinal analyses showed that IFN-γ-, IP-10-, IL-17- and VEGF-production by M. leprae
(antigen)-stimulated PBMC peaked at diagnosis of type 1 reactions, compared to when reactions were absent.
In contrast, IL-10 production decreased during type 1 reaction while increasing after treatment. Thus, ratios of
these pro-inflammatory cytokines versus IL-10 provide useful tools for early diagnosing type 1 reactions and
evaluating treatment. Of further importance for rapid diagnosis, circulating IP-10 in sera were significantly
increased during type 1 reactions. On the other hand, humoral immunity, characterized by M. leprae-specific
antibody detection, did not identify onset of type 1 reactions, but allowed treatment monitoring instead.
Conclusions: This study identifies immune-profiles as promising host biomarkers for detecting intra-individual
changes during acute inflammation in leprosy, also providing an approach for other chronic (infectious)
diseases to help early diagnose these episodes and contribute to timely treatment and prevention of tissue
damage.
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Background
Leprosy is a chronic, immunoregulatory infectious dis-
ease caused by Mycobacterium leprae that particularly
affects the skin and peripheral nerves and often results
in severe, life-long disabilities and deformities [1, 2]. The
number of new cases has plateaued at 220,000–250,000
annually, but many linger undetected [3, 4]. Leprosy re-
mains endemic in Africa, South America and Asia and
with increasing migration, new cases are detected in de-
veloped countries, where initial misdiagnosis is likely to
occur [5–7].
The inter-individual variability in clinical manifesta-
tions of leprosy closely parallels the ability of the host to
mount an effective immune response to M. leprae. This
is depicted by an immunological and clinical spectrum
in those who progress to disease, ranging between two
completely different poles i.e. tuberculoid (TT) and lep-
romatous (LL) leprosy [8]. Host resistance to M. leprae
is associated with the emergence of a protective
Thelper-1 (Th1)-based response characterized by the se-
cretion of the innate and adaptive cytokines IL-12p70,
IFN-γ, lymphotoxin-α/β, and (moderate levels of) other
pro-inflammatory cytokines such as TNF-α. LL patients
secrete predominantly anti-inflammatory mediators such
as IL-10, accompanied by the absence of Th1-associated
cytokines in response to M. leprae but characterized by
high anti-M. leprae antibody titers. Conversely, TT pa-
tients produce exacerbated levels of pro-inflammatory
cytokines, including those produced by Th17 rather than
Th1, and frequently driven by strong innate immune ac-
tivation resulting in the release of IL-1β and/or IL-6,
TGF-β and IL-23 [9, 10].
Although leprosy can be treated effectively with multi-
drug therapy (MDT), it is complicated by persisters [11]
as well as acute inflammatory episodes called leprosy re-
actions. These immunological complications, occurring
before, during and after MDT treatment in 30–50 % of
the patients, represent the major cause of leprosy-related
neurological damage [12, 13]. Two types of reactions are
recognized: type 1 or reversal reactions (RRs) and type 2
or erythema nodosum leprosum (ENL). RRs are consid-
ered a delayed hypersensitivity reaction with characteris-
tic infiltrations of skin and nerve lesions by CD4+ T-cells
producing IFN-γ and TNF-α [14–16]. Up to 30 % of
leprosy patients are affected by RRs, which most
commonly occur in borderline forms of leprosy (bor-
derline-tuberculoid (BT), borderline-borderline (BB),
borderline-lepromatous (BL)) in which concomitant im-
munological fluctuations can generate significant neuro-
pathology [17]. Prompt diagnosis and anti-reactional
treatment contributes to recovery significantly thus redu-
cing risks for permanent tissue damage [18, 19]. Unfortu-
nately, reactions are frequently misdiagnosed due to
decreased expertise within integrated health services [17].
Therefore, reliable tests for early diagnosis of RR could
make huge differences in clinical outcomes. A major obs-
tacle to developing such tests is the lack of dependable
biomarkers for reactions across endemic populations.
For the complex host immuno-pathogenicity of leprosy
[2, 14], assessment of multiple rather than single bio-
markers is more informative of the hosts’ immune status.
Therefore, we aimed to identify relevant host immune-
biomarkers for early diagnosis of type 1 reactions. We re-
cruited newly diagnosed leprosy patients longitudinally
and studied M. leprae-specific cellular- and humoral im-
munity in blood of patients 1) in the absence of any
clinical signs of reactions at least three months before re-
actions, 2) very early after clinical presentation of reac-
tions and 3) after completion of treatment. Non-reactional
patients (before and after treatment) as well as healthy
individuals from the same area were analyzed similarly.
To accommodate worldwide applicability, independent of
the genetic and environmental background, this study was
executed similarly in four distinct, prospective cohorts in
Asia, Africa and South-America.
Materials and methods
General study-procedure
Recruitment took place in Bangladesh (International Centre
for Diarrhoeal Disease Research Bangladesh, Dhaka), Brazil
(National Reference Centre for Sanitary Dermatology and
Leprosy, Uberlandia), Ethiopia (ALERT hospital and Health
Centre,) and Nepal (Mycobacterial Research Laboratories,
Kathmandu). Experiments were performed according to
standard operating procedures and each site was provided
with identical reagents.
Study participants
Patients and endemic controls (EC) were recruited on a
voluntary basis between February 2008-March 2013
(Table 1). Leprosy was diagnosed based on clinical, bac-
teriological and histological observations and classified
by skin biopsies according to Ridley and Jopling [1]. Lep-
rosy patients were treated according to WHO standards.
Clinical monitoring for reactions was performed during
monthly clinic visits. Clinical and demographic data was
collected in clinical research forms (Additional file 1)
and subsequently transferred in databases with special
emphasis on standardizing data collection and definition
of reaction between all cohorts [20, 21]. For patients
who presented with reactions the type, severity, skin-
and/or nerve involvement, number of lesions and re-
lapse were noted, according to state-of-the-art clinical
expertise and international consensus scoring [21, 22].
EC were assessed for the absence of clinical signs and
symptoms of leprosy and TB. Staff of leprosy- or TB
clinics were excluded.
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Leprosy prevalence
Dhaka, prevalence: 2.45/10,000, new case detection rate
(NCDR): 0.31/10,000 (Annual Reports of Leprosy Con-
trol Institute & Hospital, Dhaka); Uberlandia, preva-
lence: 0.96/10,000, NCDR: 1,12/10,000 (National Disease
Surveillance System, Secretariat of Health Surveillance,
Ministry of Health Brazil); Addis Ababa, prevalence: 0.6/
10,000 in 2010–2011, 0.4/10,000 in 2012, NCDR: 0.35/
10,000 (FMOH reports); Kathmandu, prevalence: 1.1-
0.79/10,000, NCDR: 1.67- 1.15/10,000 (Annual Report
2012–2013, Leprosy Control Division, Department of
Health Services, Kathmandu).
Recruitment
Newly diagnosed, untreated leprosy patients without
clinical reactions were enrolled and blood was drawn be-
fore MDT (t = 0). Patients who presented reactions
within three months of the start of therapy were ex-
cluded to avoid profile analyses of patients with latent
reactions. If patients presented with reactions after more
than three months of MDT, blood was drawn before ini-
tiation of anti-reactional therapy (t = x). Newly diagnosed
leprosy patients who visited clinics with RR were re-
cruited (t = x) but consequently lacked t = 0 samples.
From all patients, blood was collected after MDT and/or
steroid therapy (t = end). For patients with RR this was
done at least one month after completion of steroid
therapy to avoid assessment of the effect of steroids. All
patients were assessed for the absence of reactions three
months after t = end. For patients showing clinical signs
of reactions within three months after t = end, this time
point was excluded. In case patients died, moved or
withdrew from the study, preventing follow-up, their
samples were excluded. Blood was used for isolation of
peripheral blood mononuclear cells (PBMC). Superna-
tants and sera were stored at −20 °C.
Antigens
M. leprae recombinant proteins were produced as de-
scribed [23]. M. leprae whole cell sonicate was provided
through the NIH/NIAID “Leprosy Research Support”
Contract N01 AI-25469 (http://www.beiresources.org).
Cytokine/chemokine analysis
PBMC, freshly isolated from venous blood, were cul-
tured for 6 days with antigens as described [23]. IFN-γ
was determined by ELISA (U-CyTech, Utrecht, The
Netherlands) [24]. A positive, reference supernatant was
provided to all laboratories. IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IFN-γ, IP-10,
G-CSF, GM-CSF, MCP-1, MIG, MIP-1β and TNF in su-
pernatants or sera were measured using the Bio-Plex-
suspension-array-system (Bio-Rad, Veenendaal, NL) [23].
IFN-β was determined in undiluted sera (25ul) using
Procartaplex IFN-β simplex-kit (eBioscience, Hatfield,
UK) and CCL18 was determined (1:10 dilutions; 100 μl)
by ELISA (DY394 DuoSet, R & D Systems, Minneapolis,
MN) according to manufacturers’ instructions.
Serology
Antibodies against ML2028 (Ag85B) and ND-O-BSA, a
synthetic analogue of phenolic glycolipid I (PGL-I), were
determined as described [25].
Ethics
This study was performed according to the Helsinki
Declaration (2008 revision). Participants were informed
about the study-objectives, the samples and their right
to refuse to take part/withdraw from the study without
consequences for their treatment. Written informed
consent was obtained before enrolment. All patients
received treatment according to national guidelines. Eth-
ical approval of the study-protocol was obtained through
appropriate ethics committees: Ethical Review Commit-
tee of ICDDR, B (#PR-10032; #PR-2007-069); Brazilian
National Council of Ethics in Research (CONEP) and
UFU Research Ethics Committee (#499/2008); National
Health Research Ethical Review committee Ethiopia
(NERC # RDHE/127-83/08); Nepal Health Research
Council (NHR #751).
Table 1 Participating study sites and study groups
Site Categorya Mean BIb Sex ratio Age range Totalc
(M/F) (yr)
Bangladesh EC nad 0.9 20–40 20
BL/LL 2.20 5 18–61 31
RR 1.68 2.5 21–63 20
Brazil EC nad 1.3 24–76 23
BL/LL 1.51 1 22–26 25
RR 1.95 3.3 25–68 20
Ethiopia EC nad 1.8 18–45 11
BL/LL 1.25 1.7 18–52 25
RR 0.46 2.8 18–60 15
Nepal EC nad 3.6 19–28 20
BL/LL 2.96 2 35–58 13
RR 1.45 2.5 27–50 20
aEC endemic control, BL/LL borderline leprosy/ lepromatous leprosy, TT/BT
tuberculoid leprosy/ borderline tuberculoid leprosy, RR reversal reaction
(type 1 reaction)
bBI bacterial index (mean)
cTotal number of recruited individuals is indicated; samples for multiple time
points were not always included. For multiplex cytokine analysis or UPLC-ESI-TOF
MS a selected sample size was used for analysis
dnot applicable
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Statistical analysis
Differences in cytokine concentrations were analysed
with two-tailed Mann–Whitney U tests (unpaired
samples) for non-parametric distribution and Wilcoxon
matched-pairs signed rank test or paired t test for longi-
tudinal analyses using GraphPad Prism version 5.01 for
Windows (GraphPad Software, San Diego, CA, USA;
www.graphpad.com). The statistical significance level
used was p < 0.05.
Results
Recruitment of four prospective cohorts
To identify biomarkers for early type 1 reactions, blood of
newly diagnosed, untreated leprosy patients was obtained
longitudinally in Bangladesh, Brazil, Ethiopia and Nepal
(Table 1). The analysis included two samples of patients
without reactions [1. before treatment (t = 0); 2. after treat-
ment (t = end)] and three of patients who developed RR
during the study [1. in the absence of clinical signs of
reactions, at least 3 months before RR diagnosis (t = 0);
2. at RR diagnosis, before steroid-treatment (t = ×); 3.
after RR and at least one month after ending steroid-
treatment (t = end)]. Since patients were frequently diag-
nosed with RR at their first clinic-visit, it became clear that
it was not always feasible to include these first samples.
Initially, patients who developed RR within 3 months of
recruitment were excluded to avoid measuring markers
for RR already at t = 0. Similarly, patients showing clinical
signs of reactions within 3 months after ending MDT and/
or steroid treatment were excluded to prevent measuring
biomarkers of RR at t = end. For longitudinal analysis
(Fig. 1) only patients entering the study without reactions
were utilized. Due to the low frequency of untreated cases
without RR at their first clinic visits who developed RR
during this study, we also included patients with RR at
their first clinic visits (as initial RR cases) consequently
lacking the first time point (t = 0). Patients included in the
analysis after database cleaning at each site are indicated
in Table 1 and Figs. 3 and 4. For healthy individuals from
these areas with identical socio-economic background,
one sample was collected.
Longitudinal M. leprae-induced cytokine/chemokine
production during reaction development
First, we analysed M. leprae-induced cytokine production
by blood cells of RR patients for whom valid samples were
available at three time points (Bangladesh: n = 3; Brazil:
n = 4; Nepal: n = 3). All patients produced significantly
higher IFN-γ and IL-17 at RR diagnosis than before or
after treatment (Fig. 1). Also, levels of IP-10, VEGF and
IL-1β peaked at RR-onset (Additional file 2: Figure S2).
In contrast, IL-10 was virtually not produced at RR
diagnosis, compared to before diagnosis and after treat-
ment. Cytokine responses to M. leprae-unique proteins,
in particular ML2478 [23], corresponded well with re-
sponses to M. leprae (Additional file 2: Figure S1).
Since cytokines modulate each other’s effects, we
considered ratios as markers for disease-status. In-
deed, the differential cytokine production at RR onset
was even more evident from the ratios of IFN-γ/IL-10
and IL-17/IL-10 (p = 0.0032; p = 0.0033; Fig. 1), whereas
IFN-γ/IL-10 for patients who did not develop reactions
remained similar before and after treatment (Additional
file 2: Figure S3D) due to the simultaneous increase of
both IFN-γ and IL-10 after MDT treatment in non-
reactional patients (Figs. 3 and 4). The potential of cyto-
kine ratios for discrimination between RR and its absence
was also evident from the ROC (receiver operating charac-
teristics) with AUC (areas under curve) ranging from
0,955–1. IP-10/IL-10 ratios showed a similar profile, with
slightly less significance (AUC:0.79; Additional file 2:
Figure S3B-C). Thus, cytokine ratios proved valuable,
RR-associated markers as well as markers for reac-
tional treatment efficacy.
Longitudinal serological analysis during reaction
development
For detection of M. tuberculosis infection [26] and to indi-
cate M. leprae exposure [23, 27], IP-10 was reported a
useful marker. Notably, IP-10 is produced in large quan-
tities facilitating its use in field-friendly test-platforms
such as lateral flow [28]. IP-10 analysis of longitudinal sera
of reactional patients showed increased levels during RR
(Fig. 2: p = 0.0059; Additional file 2: Figure S4: AUC:0,79)
consistent with previous studies [6, 29]. Upon anti-
reactional treatment, serum IP-10 decreased (p = 0.002;
Fig. 2a). In contrast, longitudinal sera from patients
without reactions or healthy donors, as control for
RR-specificity, showed no significant difference in IP-
10, clearly designating IP-10 as a serological marker
for RR (Fig. 2).
The dynamics of CCL18 (chemokine (C-C motif ) lig-
and 18) serum levels, elevated in lepromatous leprosy
[30], were also investigated for patients experiencing
reactions (Fig. 2b), showing a decreasing trend at RR,
increasing after treatment for most patients. CCL18 in
healthy controls were much lower than for borderline
lepromatous patients in line with recent findings [30].
In view of the reduction of IL-10 during RR, these
sera were also analysed for the presence of IL-10-
inducing IFN-β [31]. Although no significant differ-
ences were detected at RR compared to before onset,
IFN-β decreased significantly after treatment (p = 0.006;
Additional file 2: Figure S6).
Cross-sectional analysis of cytokine production
Cytokine profiles produced by blood cells cultured with
M. leprae sonicate/-proteins [23] were analysed cross-
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sectionally as well (Fig. 3, Additional file 2: Figure S1,
Additional file 2: Figure S2). In line with our longitudinal
results, patients who developed RR produced signifi-
cantly higher IFN-γ levels in response to M. leprae pro-
teins at RR diagnosis than before onset of reaction or
after reaction treatment regardless of their ethnic origin
(blood at t = 0 from Ethiopian RR patients was not avail-
able). As found previously for leprosy-endemic areas, EC
produced high IFN-γ levels to M. leprae [23, 27, 32, 33].
IL-10 levels in response to M. leprae were again in
striking contrast to IFN-γ levels (Fig. 4). Virtually no re-
sponses were seen at RR diagnosis, compared to elevated
Fig. 1 Longitudinal pattern of cytokine ratios for patients with reversal reaction (RR) IFN-γ, IL-17 and IL-10 production was induced by stimulation
with M. leprae a for 10 patients who developed RR during this study (Bangladesh: n = 3; Brazil; n = 4; Nepal: n = 3) at leprosy diagnosis before
MDT in the absence of any clinical signs of reactions and at least three months before reaction (before RR), at diagnosis of reaction before steroids (RR)
or after MDT and RR, at least one month after end of steroids (after RR). IFN-γ/ IL-10 b and IL-17/ IL-10 c ratios and ROC (receiver operating characteristics)
curves are shown. For calculations of ROC values, time points before RR versus at RR diagnosis (B, C middle panels) or at RR diagnosis versus after
RR (B, C right panel) were considered
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IL-10 levels before diagnosis and after treatment. IP-10,
IL-17, VEGF and to a lesser extent IL-1β levels followed
those of IFN-γ, whereas G-CSF trended towards a de-
cline at RR (Additional file 2: Figure S2). High levels of
IL-5, IL-6, IL-8, MCP-1, MIP-1β, GM-CSF and TNF
were observed for all groups but lacked a distinct longi-
tudinal pattern, whereas induction of IL-2, IL-4, IL-7,
IL-12p70 and IL-13 was low (data not shown).
Biomarkers to monitor treatment efficacy
Besides biomarkers associated with reactions, biomarkers
to monitor treatment efficacy provide practical tools as
well. Thus, we analyzed the effect of treatment on immu-
nemarkers: IFN-γ responses to M. leprae antigens of pa-
tients without reactions increased after treatment (Fig. 3),
whereas IL-10 increased slightly, but not significantly with
treatment (Fig. 4). Treatment-induced increasing trends
were also observed for VEGF, IL-1β and IL-17A levels
(Additional file 2: Figure S2) thereby contributing to the
biomarker profile for RR. As observed for RR patients,
IFN-γ levels also increased in patients without RR after
MDT treatment. In contrast to reactional patients, how-
ever, IL-10 levels were higher after MDT which renders
the drop in IFN-γ/IL-10 ratio (Fig. 1 and Additional file 2:
Figure S3D) specifically associated with RR.
Finally, cross-sectional screening of sera for the presence
of antibodies to ND-O-BSA and ML2028 was performed
(Fig. 5 and Additional file 2: Figure S5). Anti-PGL-I IgM
levels, but not anti-ML2028 IgG levels were generally low-
est in EC. In patients without RR, treatment significant
Fig. 2 Longitudinal serum analysis of patients with reversal reaction (RR) Levels of IP-10 a and CCL18 b in unstimulated sera derived from
10 leprosy patients (left panels) developing RR (Bangladesh: n = 4; Brazil; n = 3; Ethiopia: n = 1; Nepal: n = 2) in the absence of any clinical
signs of reactions and at least three months before reaction (before RR), at diagnosis of reaction before steroids (RR) or after MDT and RR,
at least one month after end of steroids (after RR), or from healthy Dutch controls (n = 10) at two sequential time points with six months
intervals (right panels). For calculations of the ROC values, time points at least three months before RR and at RR diagnosis before steroids
were considered. IFN-β levels for controls were not detectable
Khadge et al. BMC Infectious Diseases  (2015) 15:477 Page 6 of 12
decreased antibodies (p = 0.0003 – 0.01), confirming that
these serological markers add to host profiles useful to
estimate treatment [25]. However, M. leprae-specific anti-
body detection did not identify RR, but allowed treatment
monitoring (p = 0.0001. – 0.02; the Ethiopian cohort did
not reach significance), suggesting that humoral immunity
could serve as auxiliary tool for monitoring reactional
treatment in addition to serum IP-10 and IFN-β as well as
cytokine ratio’s.
Discussion
Biomarkers as reliable correlates of disease complications
and response to therapy are essential tools for early diag-
nosis of disease states in chronic infections. Generally, the
performance of one biomarker can be significantly en-
hanced by using instead a custom-made grouping of inde-
pendent biomarkers, called a profile or signature. In the
current situation of leprosy elimination, the availability of
sensitive and specific biomarkers that aid early diagnosis
of leprosy reactions as well as monitor therapy, would be
a strategic advantage enabling health care workers to iden-
tify, treat and possibly prevent these episodes at early
stages, thereby reducing nerve damage. Since the immu-
nopathology of leprosy, particularly in reactional states, is
linked to temporal changes in the immune response to M.
leprae, leprosy represents a uniquely suitable model to
study immune-biomarker changes in relation to clinical
disease manifestations.
This is the first study in which cellular- and humoral
immunity specific for M. leprae in leprosy patients
within the three main continents reporting leprosy were
monitored longitudinally during treatment. Although
previous studies have analyzed circulating cytokines and
chemokines [29] around the time of leprosy reactions.
Fig. 3 Longitudinal cross-sectional pattern of IFN-γ and IL-10 secretion. IFN-γ (Fig. 3) or IL-10 (Fig. 4) production (corrected for background values)
in response to M. leprae sonicate (10 μg/ml) in 6 day cultures of peripheral mononuclear cells (PBMC) of endemic controls (EC;▼), newly diagnosed
leprosy patients without reactions (no Rxn;) before treatment (t = 0) and after treatment (t = end) and leprosy patients (•) in the absence of any clinical
signs of reactions and at least 3 months before RR (t = 0), at RR diagnosis before steroids (t = x) or after MDT and RR (t = end), at least one month after
end of steroids (after RR) in individuals from Bangladesh, Brazil, Ethiopia, and Nepal. All patients were assessed for the absence of reactions
three months after t = end. Background values were typically < 50 pg/ ml. The number of individuals per group and the time point are indicated below
the x-axis for each site
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The addition of an M. leprae antigen-specific compo-
nent, as utilized in this study, provides more specificity
to this approach.
The data demonstrate translational importance since
similar intra-individual trends were observed for devel-
opment of RR in different endemic areas, allowing global
application of these biomarkers in tests for early diagno-
sis of RR. In this respect, the importance of the com-
bined effect of M. leprae-induced cytokine production
(IFN-γ, IL-17, IP-10, IL-1β, VEGF), determined by their
ratios versus IL-10, was highlighted, providing valuable
tools for diagnosis of reactional states.
The biomarker profiles identified in this study for RR
can be used in blood-based diagnostic tests [28] to detect
(intra-individual) changes during these acute inflamma-
tory periods but also provide an approach for other
chronic diseases with acute inflammatory states such as
tuberculosis [34] and buruli ulcer [35] (paradoxical reac-
tions) and Crohn’s disease [36, 37], to help early diagnose
such episodes thereby contributing to timely treatment
and prevention of disease-specific tissue damage.
The acknowledged immunosuppressive role of IL-10
in lepromatous leprosy [38] as well as in M. leprae in-
fected mice [39, 40] was also evident from its reduction
at RR-onset [41]. Thus, during RR the breakdown of
regulation, in favour of inflammation, seems to underlie
the aetiology of reactional tissue damage, whereas bal-
anced ratios of these immune responses, as present in
nonreactional leprosy patients, are protective against RR
[42]. This is in line with the associations of IL-10 genetic
variants with development of leprosy and leprosy reac-
tions [6, 43–46]. Suppression of IL-10 in a borderline
tuberculoid-like murine model significantly augmented
CD4/44+ and CD8/44+ longitudinal infiltrative responses
specific to M. leprae antigens and permitted CD4+ T-
cells to penetrate and fragment nerve [47], in line with
our current field findings and supporting monitoring pa-
tient IL-10 levels in ratio to cytokines proven to escalate
Fig. 4 Longitudinal cross-sectional pattern of IFN-γ and IL-10 secretion. IFN-γ (Fig. 3) or IL-10 (Fig. 4) production (corrected for background values)
in response to M. leprae sonicate (10 μg/ml) in 6 day cultures of peripheral mononuclear cells (PBMC) of endemic controls (EC;▼), newly diagnosed
leprosy patients without reactions (no Rxn;) before treatment (t = 0) and after treatment (t = end) and leprosy patients (•) in the absence of any clinical
signs of reactions and at least 3 months before RR (t = 0), at RR diagnosis before steroids (t = x) or after MDT and RR (t = end), at least one month after
end of steroids (after RR) in individuals from Bangladesh, Brazil, Ethiopia, and Nepal. All patients were assessed for the absence of reactions
three months after t = end. Background values were typically < 50 pg/ ml. The number of individuals per group and the time point are indicated below
the x-axis for each site
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during RR as a potential early indicator of impending
clinical RR.
As a second biomarker for RR in multiple ethnic
backgrounds, increased serum IP-10 levels were iden-
tified, whereas CCL18, which is elevated in leproma-
tous leprosy [30], decreased at early RR in 6/10
patients who developed RR. Since CCL18 is secreted
by dendritic cells upon recognition of M. tuberculosis
[48] and has been implicated in differentiation of
macrophages into an alternative phenotype [49] this
suggests that decreased CCL18 levels lead to fewer al-
ternatively activated macrophages and less T-cell
regulation [6, 50]. These data therefore indicate that
new biomarker discovery approaches for RR also con-
tribute to our understanding of the RR-associated
immunopathologic mechanisms, suggesting new op-
portunities for therapeutic interventions.
Since RRs are considered delayed hypersensitivity reac-
tions caused by overreaction and/or dysregulation of
host defence mechanisms, conscientious (personalized)
treatment monitoring is vital similar to other diseases
with acute inflammatory states such as psoriasis and
Crohn’s disease which share specific susceptibility
genes with leprosy [36, 51]. Our data showed that
pro-inflammatory cytokine/IL-10 ratios, serum IP-10
can be used for monitoring treatment while not on
steroids. Therefore, besides for early diagnosis of reac-
tions, tests to monitor efficacy of treatment are useful
as well, especially in the light of the reoccurrence of
these episodes.
Fig. 5 Humoral immunity to M. leprae antigens Antibodies against synthetic PGL-I (ND-O-BSA, a synthetic analog of the M. leprae-specific PGL-I)
by ELISA. Sera were derived from Bangladesh, Brazil, Ethiopia, and Nepal and included endemic controls (EC;▼), newly diagnosed leprosy patients
without reactions (no Rxn;) before (t = 0) and after treatment (t = end) and leprosy patients (•) in the absence of any clinical signs of reactions and at
least 3 months before RR (t = 0), at RR diagnosis before steroids (t = x) or after MDT and RR, at least one month after end of steroids (t = end). Optical
density readings were performed using a 1:200 serum dilution. Median values for each group are indicated by horizontal lines. P-values < 0,05
indicate significant differences. The number of individuals per group and the time point are indicated below the x-axis for each site
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To allow access to diagnostic test at resource-poor
field settings, we recently developed low-tech, robust
lateral flow assays (LFAs) for (simultaneous) detection
of inflammatory (IP-10) and regulatory (IL-10) im-
mune responses together with anti-PGL-I IgM anti-
bodies in short term whole blood assays [28, 52]. In
the light of the currently identified immune markers
for RR, field-friendly LFAs measuring these cytokines
for leprosy patients on MDT at each clinic-visit may
be helpful to early detect RR if used for intra-
individual testing. Thus, to provide a rapid test, the
diagnostic potential of the cytokine ratios defined
here, need to be determined in future studies using
whole blood assays as well.
Conclusions
Type 1 or reversal reactions (RRs) are a major cause of
leprosy-related nerve impairment and bear similarities
with acute inflammation induced episodes in other (infec-
tious) diseases. Since there is no laboratory test for the
early diagnosis of these episodes, this multi-continental,
longitudinal study on the occurrence of RRs in leprosy
patients, showed for the first time that both M. leprae-spe-
cific cellular- as well as humoral host immune-profiles,
correlating with early onset of these inflammatory ep-
isodes, can be identified. Biomarkers associated with
diagnosis or efficiency of treatment of type 1 reac-
tions were identified, based on intra-individual changes
rather than single values. In particular, ratios of cytokines
secreted by M. leprae stimulated blood cells as well as cir-
culating cytokines in sera, contributed to these biomarker
profiles. Thus, these profiles can be applied for the early
diagnosis and to monitor reactional episodes and contrib-
ute to timely treatment and reduction/prevention of tissue
damage.
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